We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
You can subscribe to our press releases by clicking here.
3.38p0.000p
at 20-09-2024 10:37:03
15 minute delayed share price from London Stock Exchange provided by Euroland.